|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bagga S, Bracht J, Hunter S, Massirer K,
Holtz J, Eachus R and Pasquinelli AE: Regulation by let-7 and lin-4
miRNAs results in target mRNA degradation. Cell. 122:553–563. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kitade Y and Akao Y: MicroRNAs and their
therapeutic potential for human diseases: microRNAs, miR-143 and
−145, function as anti-oncomirs and the application of chemically
modified miR-143 as an anti-cancer drug. J Pharmacol Sci.
114:276–280. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M
and Rajewsky N: Combinatorial microRNA target predictions. Nat
Genet. 37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ciafrè SA, Galardi S, Mangiola A, Ferracin
M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM and Farace MG:
Extensive modulation of a set of microRNAs in primary glioblastoma.
Biochem Biophys Res Commun. 334:1351–1358. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim YK, Yu J, Han TS, Park SY, Namkoong B,
Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK and Kim VN: Functional links
between clustered microRNAs: Suppression of cell-cycle inhibitors
by microRNA clusters in gastric cancer. Nucleic Acids Res.
37:1672–1681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu WK, Law PT, Lee CW, Cho CH, Fan D, Wu
K, Yu J and Sung JJ: MicroRNA in colorectal cancer: From benchtop
to bedside. Carcinogenesis. 32:247–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Michael MZ, SM OC, van Holst Pellekaan NG,
Young GP and James RJ: Reduced accumulation of specific microRNAs
in colorectal neoplasia. Mol Cancer Res. 1:882–891. 2003.PubMed/NCBI
|
|
16
|
Takamizawa J, Konishi H, Yanagisawa K,
Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y,
et al: Reduced expression of the let-7 microRNAs in human lung
cancers in association with shortened postoperative survival.
Cancer Res. 64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pradhan AK, Emdad L, Das SK, Sarkar D and
Fisher PB: The enigma of miRNA regulation in cancer. Adv Cancer
Res. 135:25–52. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Slaby O, Svoboda M, Fabian P, Smerdova T,
Knoflickova D, Bednarikova M, Nenutil R and Vyzula R: Altered
expression of miR-21, miR-31, miR-143 and miR-145 is related to
clinicopathologic features of colorectal cancer. Oncology.
72:397–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo C, Sah JF, Beard L, Willson JK,
Markowitz SD and Guda K: The noncoding RNA, miR-126, suppresses the
growth of neoplastic cells by targeting phosphatidylinositol
3-kinase signaling and is frequently lost in colon cancers. Genes
Chromosomes Cancer. 47:939–946. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gaedcke J, Grade M, Camps J, Søkilde R,
Kaczkowski B, Schetter AJ, Difilippantonio MJ, Harris CC, Ghadimi
BM, Møller S, et al: The rectal cancer microRNAome-microRNA
expression in rectal cancer and matched normal mucosa. Clin Cancer
Res. 18:4919–4930. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shah MY, Ferrajoli A, Sood AK,
Lopez-Berestein G and Calin GA: microRNA therapeutics in cancer-an
emerging concept. EBioMedicine. 12:34–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Grady WM, Parkin RK, Mitchell PS, Lee JH,
Kim YH, Tsuchiya KD, Washington MK, Paraskeva C, Willson JK, Kaz
AM, et al: Epigenetic silencing of the intronic microRNA
hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene.
27:3880–3888. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tazawa H, Tsuchiya N, Izumiya M and
Nakagama H: Tumor-suppressive miR-34a induces senescence-like
growth arrest through modulation of the E2F pathway in human colon
cancer cells. Proc Natl Acad Sci USA. 104:15472–15477. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alqurashi N, Hashimi SM, Alowaidi F,
Ivanovski S and Wei MQ: Dual mTOR/PI3K inhibitor NVP-BEZ235 arrests
colorectal cancer cell growth and displays differential inhibition
of 4E-BP1. Oncol Rep. 40:1083–1092. 2018.PubMed/NCBI
|
|
25
|
Alowaidi F, Hashimi SM, Alqurashi N,
Alhulais R, Ivanovski S, Bellette B, Meedenyia A, Lam A and Wood S:
Assessing stemness and proliferation properties of the newly
established colon cancer ‘stem’ cell line, CSC480 and novel
approaches to identify dormant cancer cells. Oncol Rep.
39:2881–2891. 2018.PubMed/NCBI
|
|
26
|
Kiriakidou M, Nelson PT, Kouranov A,
Fitziev P, Bouyioukos C, Mourelatos Z and Hatzigeorgiou A: A
combined computational-experimental approach predicts human
microRNA targets. Genes Dev. 18:1165–1178. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk-database: Prediction of possible miRNA binding sites by
‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang X and El Naqa IM: Prediction of both
conserved and nonconserved microRNA targets in animals.
Bioinformatics. 24:325–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dowling RJ, Topisirovic I, Alain T,
Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj
A, Liu Y, et al: mTORC1-mediated cell proliferation, but not cell
growth, controlled by the 4E-BPs. Science. 328:1172–1176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Melo SA and Esteller M: Dysregulation of
microRNAs in cancer: Playing with fire. FEBS Lett. 585:2087–2099.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
AlQurashi N, Hashimi S and Wei M: Chemical
inhibitors and microRNAs (miRNA) targeting the mammalian target of
rapamycin (mTOR) pathway: Potential for novel anticancer
therapeutics. Int J Mol Sci. 14:3874–3900. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Oğul H: Computational prediction of
microRNA function and activity. Methods Mol Biol. 1107:243–256.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yan Z, Xiong Y, Xu W, Gao J, Cheng Y, Wang
Z, Chen F and Zheng G: Identification of hsa-miR-335 as a
prognostic signature in gastric cancer. PLoS One. 7:e400372012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Peng HH, Zhang YD, Gong LS, Liu WD and
Zhang Y: Increased expression of microRNA-335 predicts a favorable
prognosis in primary gallbladder carcinoma. Onco Targets Ther.
6:1625–1630. 2013.PubMed/NCBI
|
|
38
|
Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen
XM and Gao HJ: Initial study of microRNA expression profiles of
colonic cancer without lymph node metastasis. J Dig Dis. 11:50–54.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vickers MM, Bar J, Gorn-Hondermann I,
Yarom N, Daneshmand M, Hanson JE, Addison CL, Asmis TR, Jonker DJ,
Maroun J, et al: Stage-dependent differential expression of
microRNAs in colorectal cancer: Potential role as markers of
metastatic disease. Clin Exp Metastasis. 29:123–132. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sarver AL, French AJ, Borralho PM,
Thayanithy V, Oberg AL, Silverstein KA, Morlan BW, Riska SM,
Boardman LA, Cunningham JM, et al: Human colon cancer profiles show
differential microRNA expression depending on mismatch repair
status and are characteristic of undifferentiated proliferative
states. BMC Cancer. 9:4012009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bandrés E, Cubedo E, Agirre X, Malumbres
R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M and
García-Foncillas J: Identification by Real-time PCR of 13 mature
microRNAs differentially expressed in colorectal cancer and
non-tumoral tissues. Mol Cancer. 5:292006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang J, Kong X, Li J, Luo Q, Li X, Shen
L, Chen L and Fang L: miR-96 promotes tumor proliferation and
invasion by targeting RECK in breast cancer. Oncol Rep.
31:1357–1363. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pineau P, Volinia S, McJunkin K, Marchio
A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM and
Dejean A: miR-221 overexpression contributes to liver
tumorigenesis. Proc Natl Acad Sci USA. 107:264–269. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Navon R, Wang H, Steinfeld I, Tsalenko A,
Ben-Dor A and Yakhini Z: Novel rank-based statistical methods
reveal microRNAs with differential expression in multiple cancer
types. PLoS One. 4:e80032009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang L, Zhu MJ, Ren AM, Wu HF, Han WM, Tan
RY and Tu RQ: A ten-microRNA signature identified from a
genome-wide microRNA expression profiling in human epithelial
ovarian cancer. PLoS One. 9:e964722014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni
L, Zhang WG, Nan KJ, Song TS and Huang C: MicroRNA profiling of
human gastric cancer. Mol Med Rep. 2:963–970. 2009.PubMed/NCBI
|
|
47
|
Wang XY, Wu MH, Liu F, Li Y, Li N, Li GY
and Shen SR: Differential miRNA expression and their target genes
between NGX6-positive and negative colon cancer cells. Mol Cell
Biochem. 345:283–290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen WC, Lin MS, Ye YL, Gao HJ, Song ZY
and Shen XY: microRNA expression pattern and its alteration
following celecoxib intervention in human colorectal cancer. Exp
Ther Med. 3:1039–1048. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang B, Li J, Sun M, Sun L and Zhang X:
miRNA expression in breast cancer varies with lymph node metastasis
and other clinicopathologic features. IUBMB Life. 66:371–377. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gu J, Wang Y and Wu X: MicroRNA in the
pathogenesis and prognosis of esophageal cancer. Curr Pharm Des.
19:1292–1300. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sundaram P, Hultine S, Smith LM, Dews M,
Fox JL, Biyashev D, Schelter JM, Huang Q, Cleary MA, Volpert OV and
Thomas-Tikhonenko A: p53-responsive miR-194 inhibits
thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer
Res. 71:7490–7501. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang J, Zhao CY, Zhang SH, Yu DH, Chen Y,
Liu QH, Shi M, Ni CR and Zhu MH: Upregulation of miR-194
contributes to tumor growth and progression in pancreatic ductal
adenocarcinoma. Oncol Rep. 31:1157–1164. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sampson VB, Rong NH, Han J, Yang Q, Aris
V, Soteropoulos P, Petrelli NJ, Dunn SP and Krueger LJ: MicroRNA
let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt
lymphoma cells. Cancer Res. 67:9762–9770. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Du L, Schageman JJ, Subauste MC, Saber B,
Hammond SM, Prudkin L, Wistuba II, Ji L, Roth JA, Minna JD and
Pertsemlidis A: miR-93, miR-98, and miR-197 regulate expression of
tumor suppressor gene FUS1. Mol Cancer Res. 7:1234–1243. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Deng ZQ, Yin JY, Tang Q, Liu FQ, Qian J,
Lin J, Shao R, Zhang M and He L: Over-expression of miR-98 in FFPE
tissues might serve as a valuable source for biomarker discovery in
breast cancer patients. Int J Clin Exp Pathol. 7:1166–1171.
2014.PubMed/NCBI
|
|
56
|
Nagaraja AK, Creighton CJ, Yu Z, Zhu H,
Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM,
et al: A link between mir-100 and FRAP1/mTOR in clear cell ovarian
cancer. Mol Endocrinol. 24:447–463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Duan Z, Choy E, Harmon D, Liu X, Susa M,
Mankin H and Hornicek F: MicroRNA-199a-3p is downregulated in human
osteosarcoma and regulates cell proliferation and migration. Mol
Cancer Ther. 10:1337–1345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chen SM, Chen HC, Chen SJ, Huang CY, Chen
PY, Wu TW, Feng LY, Tsai HC, Lui TN, Hsueh C and Wei KC:
MicroRNA-495 inhibits proliferation of glioblastoma multiforme
cells by downregulating cyclin-dependent kinase 6. World J Surg
Oncol. 11:872013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Fornari F, Milazzo M, Chieco P, Negrini M,
Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L and Gramantieri
L: miR-199a-3p regulates mTOR and c-Met to influence the
doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res.
70:5184–5193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Formosa A, Markert EK, Lena AM, Italiano
D, Finazzi-Agro' E, Levine AJ, Bernardini S, Garabadgiu AV, Melino
G and Candi E: MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c,
miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p,
mapped to the 14q32.31 locus, regulate proliferation, apoptosis,
migration and invasion in metastatic prostate cancer cells.
Oncogene. 33:5173–5182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Jiang X, Huang H, Li Z, He C, Li Y, Chen
P, Gurbuxani S, Arnovitz S, Hong GM, Price C, et al: miR-495 is a
tumor-suppressor microRNA down-regulated in MLL-rearranged
leukemia. Proc Natl Acad Sci USA. 109:19397–19402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chu H, Chen X, Wang H, Du Y, Wang Y, Zang
W, Li P, Li J, Chang J, Zhao G and Zhang G: miR-495 regulates
proliferation and migration in NSCLC by targeting MTA3. Tumour
Biol. 35:3487–3494. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Chuang AY, Chuang JC, Zhai Z, Wu F and
Kwon JH: NOD2 expression is regulated by microRNAs in colonic
epithelial HCT116 cells. Inflamm Bowel Dis. 20:126–135. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hwang-Verslues WW, Chang PH, Wei PC, Yang
CY, Huang CK, Kuo WH, Shew JY, Chang KJ, Lee EY and Lee WH: miR-495
is upregulated by E12/E47 in breast cancer stem cells, and promotes
oncogenesis and hypoxia resistance via downregulation of E-cadherin
and REDD1. Oncogene. 30:2463–2474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Xu XH, Wu XB, Wu SB, Liu HB, Chen R and Li
Y: Identification of miRNAs differentially expressed in clinical
stages of human colorectal carcinoma-an investigation in Guangzhou,
China. PLoS One. 9:e940602014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Tan YY, Xu XY, Wang JF, Zhang CW and Zhang
SC: miR-654-5p attenuates breast cancer progression by targeting
EPSTI1. Am J Cancer Res. 6:522–532. 2016.PubMed/NCBI
|
|
67
|
Geraldo MV, Nakaya HI and Kimura ET:
Down-regulation of 14q32-encoded miRNAs and tumor suppressor role
for miR-654-3p in papillary thyroid cancer. Oncotarget.
8:9597–9607. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wang L, Liu JL, Yu L, Liu XX, Wu HM, Lei
FY, Wu S and Wang X: Downregulated miR-495 [Corrected] inhibits the
G1-S phase transition by targeting Bmi-1 in breast cancer. Medicine
(Baltimore). 94:e7182015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yan L, Yao J and Qiu J: miRNA-495
suppresses proliferation and migration of colorectal cancer cells
by targeting FAM83D. Biomed Pharmacother. 96:974–981. 2017.
View Article : Google Scholar : PubMed/NCBI
|
